



**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 29, 2024

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai – 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block Bandra-Kurla Complex, Bandra (E)  
Mumbai – 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Unaudited financial results for the quarter ended June 30, 2024 – Outcome of the Board Meeting.**

**Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results for the quarter ended June 30, 2024, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 4.00 p.m. and concluded at 7.25 p.m. Also please find enclosed the Limited Review Report by our Statutory Auditors, M/s. B. S. R. & Co., LLP, in respect of the above results.

We request you to kindly take the same on record.

Thanking you,

Your truly,  
**For Pfizer Limited**

**Prajeet Nair**  
**Director – Corporate Services & Company Secretary**

**Cc.: National Securities Depository Limited (NSDL)**  
**Central Depository Services (India) Limited (CDSL)**  
**KFin Technologies Limited**

**Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Pfizer Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



**Sadashiv Shetty**

Partner

Mumbai

29 July 2024

Membership No.: 048648

UDIN: 24048648BKFQIR8950



**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

**Statement of Unaudited Financial Results for the Quarter ended 30 June 2024**

(₹ in crore except earnings per share)

Particulars	3 months ended 30/06/2024	Preceding 3 months ended 31/03/2024	Corresponding 3 months ended in the previous year 30/06/2023	Previous year ended 31/03/2024
	Unaudited	Audited (Refer note 4)	Unaudited	Audited
<b>1 Income</b>				
(a) Revenue from operations	562.86	546.63	531.36	2,193.17
(b) Other income	41.84	75.13	33.46	180.51
<b>Total income</b>	<b>604.70</b>	<b>621.76</b>	<b>564.82</b>	<b>2,373.68</b>
<b>2 Expenses</b>				
(a) Cost of materials consumed	57.74	88.68	86.11	335.80
(b) Purchases of stock-in-trade	187.59	93.96	146.90	468.59
(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	(44.64)	6.70	(17.11)	(11.82)
(d) Employee benefits expense	91.37	75.11	93.52	347.80
(e) Finance costs	2.11	6.95	2.87	15.41
(f) Depreciation and amortization expense	14.60	13.75	15.55	62.28
(g) Other expenses	93.31	92.75	111.23	417.50
<b>Total expenses</b>	<b>402.08</b>	<b>377.90</b>	<b>439.07</b>	<b>1,635.56</b>
<b>3 Profit before tax and exceptional items (1 - 2)</b>	<b>202.62</b>	<b>243.86</b>	<b>125.75</b>	<b>738.12</b>
<b>4 Exceptional items (Refer Note 5)</b>	-	-	-	7.95
<b>5 Profit before tax (3 + 4)</b>	<b>202.62</b>	<b>243.86</b>	<b>125.75</b>	<b>746.07</b>
<b>6 Tax expense</b>				
(a) Current tax	55.05	48.98	33.43	158.92
(b) Deferred tax	(3.14)	16.31	(1.21)	36.11
(c) Tax adjustments for earlier years	-	(0.29)	-	(0.29)
<b>7 Net profit for the period / year (5 - 6)</b>	<b>150.71</b>	<b>178.86</b>	<b>93.53</b>	<b>551.33</b>
<b>8 Other comprehensive income</b>				
(a) Items that will not be reclassified subsequently to profit or loss	(0.72)	10.59	(1.10)	7.28
(b) Income tax related to items that will not be reclassified to profit or loss	0.18	(2.66)	0.28	(1.83)
Other comprehensive income, net of taxes	(0.54)	7.93	(0.82)	5.45
<b>9 Total comprehensive income for the period / year (7 + 8)</b>	<b>150.17</b>	<b>186.79</b>	<b>92.71</b>	<b>556.78</b>
<b>10 Paid-up equity share capital (Face value per share ₹10)</b>	<b>45.75</b>	<b>45.75</b>	<b>45.75</b>	<b>45.75</b>
<b>11 Other equity</b>				<b>3,549.79</b>
<b>12 Earnings per share - Basic and Diluted (of ₹10/- each) #</b>				
Computed on the basis of net profit for the period / year	32.94*	39.09*	20.44*	120.51

# Earnings per share - Basic and Diluted before Exceptional items

\*Not annualised

CIN: [L24231MH1950PLC008311](#)  
Email ID: [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)  
Website: [www.pfizerindia.co.in](http://www.pfizerindia.co.in)



**NOTES:**

1. The above financial results were reviewed by the Audit Committee, and thereafter approved by the Board of Directors at their meeting held on July 29, 2024.
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
3. The financial results for the quarter ended June 30, 2024 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - [www.pfizerltd.co.in](http://www.pfizerltd.co.in)
4. Figures for the quarter ended March 31, 2024 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2023 which were subject to a limited review by the statutory auditors.
5. Exceptional item for the year ended March 31, 2024 is in relation to provision for old pending VAT / CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years and had received final settlement orders. Pursuant to the said orders the Company had written back excess provision of ₹ 7.95 crore.
6. The Company has only one segment which is 'Pharmaceuticals'. Therefore disclosure relating to segments is not applicable and accordingly not made.

July 29, 2024

For Pfizer Limited



Meenakshi Nevatia  
Managing Director